BBNBonkers Broadcasting NetworkSaturday, October 10, 2026Sat, Oct 10Watch live

U.S.

AbbVie Cuts Guidance; Bond Rout Draws Savers

On air: Hank Ledger, Dale Bearman and Vera Bullock on After the Bell
Published

At a glance

  • First reported by Benzinga: “AbbVie Lowers FY2026 Adjusted EPS Guidance To $13.76-$13.96/Share, Q3 To $3.73-$3.77/Share, On $216M Acquired R&D And Milestone Expense”, with reporting from MarketWatch.
  • Covered on BBN on Monday, October 5, 2026, at 4:21 PM ET on After the Bell, by Hank Ledger, Dale Bearman and Vera Bullock.
  • Topics: AbbVie, EPS.
  • BBN covered this story before: Genmab, AbbVie Lymphoma Data Lifts Epkinly Outlook (October 5).

The real story

The reporting behind this segment. The headlines belong to the outlets; read the original before you believe or share anything.

  • BenzingaAbbVie Lowers FY2026 Adjusted EPS Guidance To $13.76-$13.96/Share, Q3 To $3.73-$3.77/Share, On $216M Acquired R&D And Milestone Expense
  • MarketWatchInvestors see big opportunity in ferocious 2026 bond-market rout
▶ Watch BBN liveMore U.S. →

The story so far

  1. Genmab, AbbVie Lymphoma Drug Hits Phase 3 Goal · GlobeNewswire Inc.
  2. Genmab, AbbVie Lymphoma Data Lifts Epkinly Outlook · Seeking Alpha
  3. AbbVie Cuts Guidance; Bond Rout Draws Savers (this story)
  4. AI Chips Surge, AbbVie Cancer Combo, Cowbell Mystery · Bloomberg.com
  5. Microsoft Falls 6.8% in 4 Minutes; Bitcoin Candle Probed · Benzinga
  6. CORRECTION: Penguin Solutions Sees FY2027 Adj EPS $3.75-$5.15 vs $3.25 · Benzinga
  7. Penguin Solutions guides FY2027 sales near $2.43 billion · Seeking Alpha

From the archive: everything BBN aired on Monday, October 5, 2026 · the U.S. archive · all months

More in U.S.

All U.S. →